Deep-Dive Due Diligence AI Generated Probe of Lexeo Therapeutics, Inc. Common Stock (LXEO)
Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.
These auto-generated reports apply OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
LXEO_OUT_1 [2025-03-24 10:49:15 -0400] 2161 Bytes | 589 tokens | Cum: 589 tkns (7.36% of 8k)
==========================================================================
We are in the 'Lightning Round' baby! It's 10:49:13 AM on Mon Mar 24, 2025 -0400, and I'm firing up the spotlight on Lexeo Therapeutics (LXEO), moving from 2.71 to 3.57. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!
Here's the first list of news for Lexeo Therapeutics:
C1 - Today 07:00AM - Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
C2 - Jan-07-25 07:30AM - Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
C3 - Dec-19-24 07:00AM - Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
C4 - Dec-02-24 07:00AM - Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024
C5 - Nov-13-24 07:30AM - Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
C6 - Oct-30-24 06:14AM - Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference
C7 - Oct-22-24 07:30AM - Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference
C8 - Sep-05-24 07:30AM - Lexeo Therapeutics to Participate in Upcoming Investor Conferences
ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Lexeo Therapeutics (LXEO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".
LXEO_IN_2 [2025-03-24 10:49:15 -0400] 2 Bytes | 2 tokens | Cum: 591 tkns (7.39% of 8k)
==========================================================================
C6
LXEO_OUT_3 [2025-03-24 10:49:24 -0400] 1039 Bytes | 293 tokens | Cum: 884 tkns (11.05% of 8k)
==========================================================================
Showing C6 (chunk 1 of 11): C6:
**Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference**
Date: Oct-30-24 06:14AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2024/10/30/2971504/0/en/Lexeo-Therapeutics-Announces-Positive-Interim-Data-for-LX1001-First-Ever-Gene-Therapy-to-Impact-the-Underlying-Genetic-Cause-of-APOE4-Associated-Alzheimer-s-Disease-at-the-Clinical.html
October 30, 2024 06:14 ET| Source:Lexeo TherapeuticsLexeo Therapeutics
Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months
Consistent reductions across CSF tau biomarkers and tau PET in majority of participants
LX1001 well tolerated across all dose cohorts with no reports of amyloid-re
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LXEO_IN_4 [2025-03-24 10:49:24 -0400] 560 Bytes | 118 tokens | Cum: 1002 tkns (12.53% of 8k)
==========================================================================
Lexeo Therapeutics has announced positive interim data for LX1001, a gene therapy aimed at impacting the genetic cause of Alzheimer's disease linked with APOE4. This data, presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference, showcases a dose-dependent increase in the neuroprotective APOE2 expression in all participants for up to 12 months. Additionally, the therapy resulted in consistent reductions in CSF tau biomarkers and tau PET in most participants. LX1001 was well-tolerated across all dose cohorts with no reports of amyloid-re.
LXEO_OUT_5 [2025-03-24 10:49:26 -0400] 1021 Bytes | 288 tokens | Cum: 1290 tkns (16.12% of 8k)
==========================================================================
We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.
A1 - 2025-03-24T11:23:11Z - Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highl...
A2 - 2025-03-24T11:16:56Z - Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highl...
A3 - 2025-03-24T11:15:39Z - Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highl...
A4 - 2025-03-20T10:25:49Z - Privium Fund Management B.V. Takes $909,000 Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)...
A5 - 2025-03-08T07:29:47Z - Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Buy" by Analysts...
Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.
LXEO_IN_6 [2025-03-24 10:49:26 -0400] 2 Bytes | 2 tokens | Cum: 1292 tkns (16.15% of 8k)
==========================================================================
A1
LXEO_OUT_7 [2025-03-24 10:49:33 -0400] 1041 Bytes | 265 tokens | Cum: 1557 tkns (19.46% of 8k)
==========================================================================
Showing A1 (chunk 1 of 14): A1:
**Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights**Date: 2025-03-24Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/03/24/tmt-newswire/globenewswire/lexeo-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-operational-highlights/2078635Codexis Announces First Revenue-Generating Contract for ECO Synthesis™ Manufacturing Services
Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be evaluated for any increase from baseline rather than numerical threshold
Interim update from cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial: observed 71% and 115% increases in PKP2 protein
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LXEO_IN_8 [2025-03-24 10:49:33 -0400] 577 Bytes | 120 tokens | Cum: 1677 tkns (20.96% of 8k)
==========================================================================
Lexeo Therapeutics has reported its financial results for the fourth quarter and full year of 2024. The report includes several operational highlights, among which is the announcement of an agreement with the FDA regarding the planned pivotal study of LX2006. This study will include a protein expression co-primary endpoint based on improvements in LVMI across participants with abnormal LVMI at baseline. The company also provided an interim update from the first cohort of its LX2020 HEROIC-PKP2 Phase 1/2 trial, which has observed increases of 71% and 115% in PKP2 protein.
LXEO_OUT_9 [2025-03-24 10:49:35 -0400] 925 Bytes | 291 tokens | Cum: 1968 tkns (24.60% of 8k)
==========================================================================
This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!
B1 - 2024-08-12T11:00:00Z - Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
B2 - 2024-07-15T10:02:11Z - Lexeo Therapeutics Announces Positive Interim Phase 1/2 - GlobeNewswire
B3 - 2024-05-14T16:00:10Z - What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
B4 - 2024-05-14T13:55:15Z - Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
B5 - 2024-05-09T11:00:00Z - Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
B6 - 2024-05-07T11:30:00Z - Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.
LXEO_IN_10 [2025-03-24 10:49:35 -0400] 2 Bytes | 2 tokens | Cum: 1970 tkns (24.62% of 8k)
==========================================================================
B1
LXEO_OUT_11 [2025-03-24 10:49:40 -0400] 809 Bytes | 200 tokens | Cum: 2170 tkns (27.12% of 8k)
==========================================================================
Showing B1 (chunk 1 of 1): B1:
**Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/08/12/2928252/0/en/Lexeo-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Operational-Highlights.htmlLexeo Therapeutics reported positive interim data from Phase 1/2 studies in Friedreich ataxia cardiomyopathy, showing LX2006 was well-tolerated and demonstrated evidence of sustained treatment effect. The company also initiated formal engagements with the FDA on surrogate endpoints for a registrational study and expects to provide an update by the end of 2024.
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LXEO_IN_12 [2025-03-24 10:49:40 -0400] 458 Bytes | 87 tokens | Cum: 2257 tkns (28.21% of 8k)
==========================================================================
Lexeo Therapeutics has released its financial results for the second quarter of 2024, with operational highlights including positive interim data from Phase 1/2 studies on Friedreich ataxia cardiomyopathy, demonstrating that LX2006 was well tolerated and showed a sustained treatment effect. The company is in formal discussions with the FDA regarding surrogate endpoints for a registrational study and anticipates providing an update by the end of the year.
LXEO_OUT_13 [2025-03-24 10:49:42 -0400] 805 Bytes | 196 tokens | Cum: 2453 tkns (30.66% of 8k)
==========================================================================
This is our list of SEC filings.
If empty, the search returned no recent filings.
S1 - 2025-03-24 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.
You should read the following discussion and analysis of our financial condition and results of operations together with the financial statements and related notes included elsewhere ...
S2 - 2025-03-24 8-K Item 2.02 Results of Oper and Fin Cond.
On March 24, 2025, Lexeo Therapeutics, Inc. (the Company ) issued a press release announcing business highlights and its financial results for the three and twelve months ended December 31, 2024. A copy of this press rele...
Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.
LXEO_IN_14 [2025-03-24 10:49:42 -0400] 2 Bytes | 2 tokens | Cum: 2455 tkns (30.69% of 8k)
==========================================================================
S1
LXEO_OUT_15 [2025-03-24 10:49:43 -0400] 1038 Bytes | 202 tokens | Cum: 2657 tkns (33.21% of 8k)
==========================================================================
Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with the financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in Item 1A. Risk Factors and in other parts of this Annual Report on Form 10-K.
Overview
We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfoli
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LXEO_IN_16 [2025-03-24 10:49:43 -0400] 3 Bytes | 2 tokens | Cum: 2659 tkns (33.24% of 8k)
==========================================================================
MOR
LXEO_OUT_17 [2025-03-24 10:49:45 -0400] 1038 Bytes | 229 tokens | Cum: 2888 tkns (36.10% of 8k)
==========================================================================
Showing S1 (chunk 2 of 6): o of therapeutic candidates that take aim at the underlying genetic causes of conditions, including FA cardiomyopathy, PKP2 arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need.
Our most advanced cardiovascular product candidate, LX2006 for the treatment of FA cardiomyopathy, is currently being evaluated in SUNRISE-FA, our ongoing Phase 1/2 clinical trial and in a Cornell investigator-initiated trial. In July 2024, we provided an interim clinical update, which included baseline characteristics from the 11 treated participants across the two studies and data from the 8 participants who had reached at least 6-months of follow-up as of that time. These data showed improvements in key cardiac biomarkers including left ventricular mass index, lateral wall thickness, and high-sensitivity troponin I. Additionally, in November 2024 we reported that we observed an
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LXEO_IN_18 [2025-03-24 10:49:45 -0400] 3 Bytes | 2 tokens | Cum: 2890 tkns (36.12% of 8k)
==========================================================================
MOR
LXEO_OUT_19 [2025-03-24 10:49:46 -0400] 1038 Bytes | 234 tokens | Cum: 3124 tkns (39.05% of 8k)
==========================================================================
Showing S1 (chunk 3 of 6): increase in frataxin protein expression in the hearts of four patients that had undergone cardiac biopsies (cohort 1 (n=1), cohort 2 (n=3)) as measured by LCMS and immunohistochemistry. LX2006 has been generally well-tolerated across both trials to date. One year after dosing, one participant with multiple comorbidities and a history of flu-like symptoms presented with Grade 2 asymptomatic myocarditis. Six weeks later, a biopsy was negative for myocarditis and the participant remains asymptomatic. In November 2024 we announced alignment with the FDA on key elements of a registrational development plan for LX2006, including an accelerated approval pathway with left ventricular mass index and frataxin protein expression as co-primary registrational endpoints. In February 2025, we reached further alignment with FDA that the frataxin protein expression co-primary endpoint would be evaluated
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LXEO_IN_20 [2025-03-24 10:49:46 -0400] 3 Bytes | 2 tokens | Cum: 3126 tkns (39.07% of 8k)
==========================================================================
MOR
LXEO_OUT_21 [2025-03-24 10:49:48 -0400] 1038 Bytes | 242 tokens | Cum: 3368 tkns (42.10% of 8k)
==========================================================================
Showing S1 (chunk 4 of 6): for any increase from baseline in frataxin positive area as measured by immunohistochemistry as opposed to any specific numerical threshold. We expect to provide a further interim data update in mid-2025.
Our second most advanced cardiovascular product candidate, LX2020 for the treatment of ACM caused by mutations in the PKP2 gene, referred to as PKP2-ACM, is currently being evaluated in HEROIC-PKP2, an ongoing Phase 1/2 clinical trial. To date, six participants have been enrolled in this trial: three in cohort 1 and three in cohort 2. We have obtained post-treatment cardiac biopsies from two participants in cohort 1; the third cohort 1 participant elected to not undergo the post-treatment biopsy procedure. In these two participants with post-treatment samples, we have observed an increase in PKP2 protein expression in the heart quantified using western blot assay showing a 71% and 115
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LXEO_IN_22 [2025-03-24 10:49:48 -0400] 3 Bytes | 2 tokens | Cum: 3370 tkns (42.12% of 8k)
==========================================================================
MOR
LXEO_OUT_23 [2025-03-24 10:49:50 -0400] 1038 Bytes | 219 tokens | Cum: 3589 tkns (44.86% of 8k)
==========================================================================
Showing S1 (chunk 5 of 6): % increase in PKP2 protein expression versus pre-treatment baseline. In addition, the first participant to reach 6 months post-treatment experienced a 67% reduction in PVCs from baseline and normalization of QRS duration. Across all participants dosed, LX2020 has been generally well-tolerated with no treatment-related serious adverse events to date. We expect to provide an interim data readout focused on clinical efficacy biomarkers in the second half of 2025.
Each of our gene therapy candidates utilizes the vector construct, dose and route of administration that we believe will result in the most favorable biodistribution and safety profile for our product candidate for each disease. Our most advanced programs use the AAVrh10 vector due to its high transduction efficiency in myocardial cells, potential for lower toxicity given the opportunity to utilize lower doses compared to other w
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LXEO_IN_24 [2025-03-24 10:49:50 -0400] 3 Bytes | 2 tokens | Cum: 3591 tkns (44.89% of 8k)
==========================================================================
MOR
LXEO_OUT_25 [2025-03-24 10:49:54 -0400] 647 Bytes | 145 tokens | Cum: 3736 tkns (46.70% of 8k)
==========================================================================
Showing S1 (chunk 6 of 6): ell-established AAV serotypes, and low pre-existing immunity.
To date, we have funded our operations primarily through proceeds from the sale of shares of our convertible preferred stock and common stock, including our Private Placement, IPO and the subsequent partial exercise of the underwriters 30-day option to purchase additional shares of common stock. As of December 31, 2024, we had $128.5 million of cash, cash equivalents, and investments. We have incurred significant operating losses since ...
-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)
LXEO_IN_26 [2025-03-24 10:49:54 -0400] 446 Bytes | 86 tokens | Cum: 3822 tkns (47.77% of 8k)
==========================================================================
The company has primarily funded its operations through the sale of shares of its convertible preferred stock and common stock, including through a Private Placement, IPO, and a subsequent partial exercise of the underwriters' 30-day option to purchase additional shares. As of December 31, 2024, the company had $128.5 million in cash, cash equivalents, and investments. The company has incurred significant operating losses since its inception.
LXEO_OUT_27 [2025-03-24 10:50:09 -0400] 6126 Bytes | 1767 tokens | Cum: 5589 tkns (69.86% of 8k)
==========================================================================
This is our set of metrics.
Please analyze the numbers.
+---------------------+-----------------------+-----------------------+-------------------------+-----------------------+----------------------+
| Volume: 3,294,053 | SMA50: -13.10% | Market Cap: 120.69M | Option/Short: Yes / Yes | Sales past 5Y: 19.69% | Sales Surprise: - |
+---------------------+-----------------------+-----------------------+-------------------------+-----------------------+----------------------+
| Avg Volume: 333.84K | SMA200: -59.40% | Shs Outstand: 33.06M | Short Float: 9.76% | Employees: 58 | EPS Surprise: 3.36% |
+---------------------+-----------------------+-----------------------+-------------------------+-----------------------+----------------------+
| Rel Volume: 48.50 | Perf Week: 17.36% | Shs Float: 24.93M | Short Ratio: 7.29 | Debt/Eq: 0.07 | P/E: - |
+---------------------+-----------------------+-----------------------+-------------------------+-----------------------+----------------------+
| RSI (14): 54.45 | Perf Month: -6.17% | Inst Own: 83.49% | Short Interest: 2.43M | Sales Y/Y TTM: - | Earnings: Mar 24 BMO |
+---------------------+-----------------------+-----------------------+-------------------------+-----------------------+----------------------+
| ATR (14): 0.45 | Perf Quarter: -42.61% | Insider Own: 24.61% | Beta: 2.81 | ROE: -107.21% | |
+---------------------+-----------------------+-----------------------+-------------------------+-----------------------+----------------------+
| SMA20: 26.22% | Index: RUT | Insider Trans: -0.06% | Sales Q/Q: - | ROI: -58.89% | |
+---------------------+-----------------------+-----------------------+-------------------------+-----------------------+----------------------+
The next section covers any insider trading.
If this section may be blank due to no recent filings.
Inside Trans: Lexeo Therapeutics, Inc. (LXEO) by Robertson Jenny (Chief Legal Officer) on 2025-02-19
- Common Stock: 2101 shares at $4.413 (D) Footnote: Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
Inside Trans: Lexeo Therapeutics, Inc. (LXEO) by Adler Eric (Chief Medical Officer) on 2025-02-19
- Common Stock: 2359 shares at $4.413 (D) Footnote: Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
Inside Trans: Lexeo Therapeutics, Inc. (LXEO) by See Tai Sandi (Chief Development Officer) on 2025-02-19
- Common Stock: 1486 shares at $4.413 (D) Footnote: Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
Inside Trans: Lexeo Therapeutics, Inc. (LXEO) by Townsend Richard Nolan (Chief Executive Officer) on 2025-02-19
- Common Stock: 4326 shares at $4.413 (D) Footnote: Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
Inside Trans: Lexeo Therapeutics, Inc. (LXEO) by Rasbach Kyle (Chief Financial Officer) on 2025-01-17
- Common Stock: 40875 shares at $0 (D)
- Stock Option (right to buy): 245250 shares at $0 (D)
Inside Trans: Lexeo Therapeutics, Inc. (LXEO) by Adler Eric (Chief Medical Officer) on 2025-01-07
- Common Stock: 43750 shares at $0 (D)
- Stock Option (right to buy): 87500 shares at $0 (D)
Inside Trans: Lexeo Therapeutics, Inc. (LXEO) by See Tai Sandi (Chief Development Officer) on 2025-01-07
- Common Stock: 38750 shares at $0 (D)
- Stock Option (right to buy): 77500 shares at $0 (D)
Inside Trans: Lexeo Therapeutics, Inc. (LXEO) by Robertson Jenny (Chief Legal & Admin Officer) on 2025-01-07
- Common Stock: 36250 shares at $0 (D)
- Stock Option (right to buy): 72500 shares at $0 (D)
[Company Financial Summary]
[Company Details]
Name: Lexeo Therapeutics, Inc. Common Stock
Market Cap: 89640146.95
Shares Outstanding: 33077545
Sector: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -29489000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A
[Price Metrics - Last 30 Days]
Latest Close: 3.46
Average Volume: 671783.62
30-Day High: 3.73
30-Day Low: 2.34
[Detailed Financials: Q3 2024]
- Total Assets: $173,865,000.0
- Total Liabilities: $34,539,000.0
- Total Equity: $139,326,000.0
- Current Assets: $159,458,000.0
- Current Liabilities: $26,818,000.0
[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.89
[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-17,961,000.0
[Detailed Financials: Q2 2024]
- Total Assets: $192,007,000.0
- Total Liabilities: $27,059,000.0
- Total Equity: $164,948,000.0
- Current Assets: $177,149,000.0
- Current Liabilities: $18,877,000.0
[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.64
[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-20,079,000.0
==== END OF FINANCIAL REPORT ====
You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.
Now, complete this report with the following:
1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]
1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE
LXEO_IN_28 [2025-03-24 10:50:09 -0400] 1072 Bytes | 236 tokens | Cum: 5825 tkns (72.81% of 8k)
==========================================================================
1) Brief Summary: Lexeo Therapeutics, Inc. (LXEO) has been experiencing a significant downward trend over the last few months. SMA50 and SMA200 are both negative, at -13.10% and -59.40% respectively, indicating a bearish market. The company’s performance over the week has been positive with a 17.36% increase but the performance over the month and quarter are negative, at -6.17% and -42.61% respectively. The insider transaction data shows that there have been some sales to cover tax obligations on the release of restricted stock units. The company's financials reveal negative net income and negligible revenue which is concerning.
2) MARKET_SCORE[35]: Given the significant negative SMA200 and SMA50, coupled with the negative quarterly performance, the likelihood of an upward move is estimated at 35%.
3) PRICE_TARGET[$4.50]: Considering the current downward trend and the financial performance, a moderate increase from its recent closing price is projected.
4) AI_RPT_HEADLINE: "Lexeo Therapeutics Grapples with Bearish Market Amidst Challenging Financials"
LXEO_OUT_29 [2025-03-24 10:50:14 -0400] 676 Bytes | 167 tokens | Cum: 5992 tkns (74.90% of 8k)
==========================================================================
Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)
LXEO_IN_30 [2025-03-24 10:50:14 -0400] 436 Bytes | 86 tokens | Cum: 6078 tkns (75.98% of 8k)
==========================================================================
As a financial analyst, I would choose X2 - More SEC filings (10-K, 10-Q, 8-K). Financials, risk disclosures, and business changes. These documents provide comprehensive information about the company's overall financial health, including its assets, liabilities, revenues, and expenses. They also contain details about the company's operations, strategies, and risk factors, which can be crucial in making informed investment decisions.
LXEO_IN_31 [2025-03-24 10:50:15 -0400] 126 Bytes | 29 tokens | Cum: 6107 tkns (76.34% of 8k)
==========================================================================
====================================
[2025-03-24 07:50:15] # Analysis Completed
Elapsed Time: 62.26 seconds